Product Description
Benserazide is a carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Benserazide)
Mechanisms of Action: DDC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Denmark | Estonia | Finland | France | Germany | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Malaysia | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Parkinson's Disease|Healthy Volunteers
Phase 2: Anemia, Sickle Cell|beta-Thalassemia
Phase 1: Parkinson's Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400084562 | N/A |
Not yet recruiting |
Osteonecrosis |
2027-02-01 |
|
| ChiCTR2200058725 | N/A |
Not yet recruiting |
Parkinson's Disease |
2026-03-31 |
|
| PB04-001 | P2 |
Recruiting |
beta-Thalassemia|Anemia, Sickle Cell |
2024-12-31 |
|
| AnkaraAtaturkSTRH-KORUCU-001 | P4 |
Enrolling by invitation |
Parkinson's Disease |
2024-10-31 |